Biomarin Pharmaceutical (BMRN) Receivables - Net (2009 - 2026)
Biomarin Pharmaceutical's (BMRN) quarterly Receivables - Net came in at $903.9 million in Q1 2026, up 22.29% YoY from $739.2 million in Q1 2025, and little changed on a QoQ basis from $908.2 million in Q4 2025.
Biomarin Pharmaceutical (BMRN) Receivables - Net (2009 - 2026) Analysis & Trends
Biomarin Pharmaceutical (BMRN) has 18 years of Receivables - Net data on file, last reported at $903.9 million in Q1 2026.
- Quarterly Receivables - Net rose 22.29% year-over-year to $903.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $903.9 million (up 22.29% YoY) and the FY2025 annual result came in at $908.2 million, up 37.5% from the prior year.
- Receivables - Net steadied at $903.9 million in Q1 2026, from $908.2 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $908.2 million in Q4 2025 to a low of $419.6 million in Q3 2022.
- A 5-year average of $656.2 million and a median of $637.2 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2023 — Receivables - Net jumped 39.0% — and 2025, when it advanced 1.64%.
- Tracing BMRN's Receivables - Net over 5 years: stood at $461.3 million in 2022, then jumped by 37.37% to $633.7 million in 2023, then advanced by 4.23% to $660.5 million in 2024, then surged by 37.5% to $908.2 million in 2025, then fell by 0.47% to $903.9 million in 2026.
- The last three Receivables - Net figures came in at $903.9 million (Q1 2026), $908.2 million (Q4 2025), and $790.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Biomarin Pharmaceutical | 13.04 Bn | 12.16 Bn | 786.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.06 Bn |
| Jun 30, 2026 | 1.06 Bn |
| Mar 31, 2026 | 903.91 Mn |
| Mar 31, 2026 | 903.91 Mn |
| Dec 31, 2025 | 908.21 Mn |
| Dec 31, 2025 | 908.21 Mn |
| Sep 30, 2025 | 790.27 Mn |
| Sep 30, 2025 | 790.27 Mn |
| Jun 30, 2025 | 855.86 Mn |
| Jun 30, 2025 | 855.86 Mn |
| Mar 31, 2025 | 739.18 Mn |
| Mar 31, 2025 | 739.18 Mn |
| Dec 31, 2024 | 660.54 Mn |
| Dec 31, 2024 | 660.54 Mn |
| Sep 30, 2024 | 777.55 Mn |
| Sep 30, 2024 | 777.55 Mn |
| Jun 30, 2024 | 691.23 Mn |
| Jun 30, 2024 | 691.23 Mn |
| Mar 31, 2024 | 637.16 Mn |
| Mar 31, 2024 | 637.16 Mn |